Xoma Corp. ( (XOMA) ) has released its Q3 earnings. Here is a breakdown of the information Xoma Corp. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xoma Corp., a biotech royalty aggregator, focuses on acquiring economic rights to future milestone and royalty payments from partnered therapeutic candidates in the biotech sector. In its latest earnings report, Xoma Corp. reported a significant turnaround with a net income of $14.1 million for the third quarter of 2025, compared to a net loss of $17.2 million in the same period last year. The company’s revenue more than doubled to $9.4 million, driven by increased income from purchased receivables and strategic acquisitions. Key financial highlights include a substantial gain from acquisitions and a reduction in operating expenses, contributing to the positive financial performance. Looking ahead, Xoma Corp. remains optimistic about its financial health, supported by a strong cash position and a strategic focus on expanding its portfolio of royalty rights, which is expected to drive future growth.